US Pharma MarketingThe post Arrowhead reports top-line results in mixed hyperlipidaemia trial appeared first on Clinical Trials Arena.
Arrowhead reports top-line results in mixed hyperlipidaemia trial
Arrowhead Pharmaceuticals has reported interim top-line results from an ongoing Phase I/IIa clinical trial investigating ARO-DIMER-PA to treat mixed hyperlipidaemia. The interim analysis showed ARO-DIMER-PA reduced serum PCSK9 by 72% and APOC3 by 88% in individuals. The trial will assess the safety, pharmacokinetics, pharmacodynamics, and lipid effects in 78 adults. Credit: PeopleImages / Shutterstock.com. Arrowhead Pharmaceuticals has reported interim top-line results from an ongoing Phase I/IIa clinical trial investigating ARO-DIMER-PA to treat mixed hyperlipidaemia. ARO-DIMER-PA is being developed for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidaemia. NPVM: Arrowhead Pharmaceuticals Inc's AROAPOC-3 Go deeper with GlobalData The gold standard of…
Arrowhead Pharmaceuticals has reported interim top-line results from an ongoing Phase I/IIa clinical trial investigating ARO-DIMER-PA to treat mixed hyperlipidaemia.
Source: Clinical Trials Arena